Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488] (European Journal of Cancer (2015) 51(4) (482–488), (S0959804915000040), (10.1016/j.ejca.2014.12.015));Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer

European Journal of Cancer

Volumn 51, Issue 4, 2015, Pages 482-488

  Ryu, Min Hee ^a   Yoo, Changhoon ^a   Kim, Jong Gwang ^b   Ryoo, Baek Yeol ^a   Park, Young Soo ^a   Park, Sook Ryun ^a   Han, Hye Suk ^c   Chung, Ik Joo ^d   Song, Eun Kee ^e   Lee, Kyung Hee ^f   Kang, Seok Yun ^g   Kang, Yoon Koo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Chungbuk National University College of Medicine   (South Korea)

^d Chonnam National University Medical School   (South Korea)

^e Chonbuk National University Medical School   (South Korea)

^f Yeungnam University Hospital   (South Korea)

^g Ajou University School of Medicine   (South Korea)

Author keywords

Capecitabine; Gastric cancer; HER2; Oxaliplatin; Trastuzumab

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; OXALIPLATIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; FLUOROURACIL; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ADVANCED GASTRIC CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERPIGMENTATION; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; STOMACH NEOPLASMS;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84924953200     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2021.01.019     Document Type: Erratum

References (18)

1. K.-W. Jung, Y.-J. Won, H.-J. Kong, C.-M. Oh, D.H. Lee, and J.S. Lee Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011 Cancer Res Treat 46 2014 109 123
2. L. Shen, Y.-S. Shan, H.-M. Hu, T.J. Price, B. Sirohi, and K.-H. Yeh Management of gastric cancer in Asia: resource-stratified guidelines Lancet Oncol 14 2013 e535 e547
3. C. Gravalos, and A. Jimeno HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target Ann Oncol 19 2008 1523 1529
4. M. Hofmann, O. Stoss, D. Shi, R. Büttner, M. van de Vijver, and W. Kim Assessment of a HER2 scoring system for gastric cancer: results from a validation study Histopathology 52 2008 797 805
5. N. Boku HER2-positive gastric cancer Gastric Cancer 17 2013 1 12
6. Y.-J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, and A. Sawaki Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
7. Y.-K. Kang, D.H. Yoon, B.-Y. Ryoo, and M.-H. Ryu Recent advances in chemotherapy for advanced gastric cancer APJOH 2 2010 67 74
8. Y.K. Kang, W.K. Kang, D.B. Shin, J. Chen, J. Xiong, and J. Wang Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial Ann Oncol 20 2009 666 673
9. D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, and F. Coxon Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 358 2008 36 46
10. S.E. Al-Batran, J.T. Hartmann, S. Probst, H. Schmalenberg, S. Hollerbach, and R. Hofheinz Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie J Clin Oncol 26 2008 1435 1442
11. D. Cunningham, A.F.C. Okines, and S. Ashley Capecitabine and oxaliplatin for advanced esophagogastric cancer N Engl J Med 362 2010 858 859
12. Y.S. Park, H.S. Hwang, H.J. Park, M.-H. Ryu, H.-M. Chang, and J.H. Yook Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 43 2012 413 422
13. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
14. R. Simon Optimal two-stage designs for phase II Clinical Trials 2002 1 10
15. Y.H. Park, J.-L. Lee, B.-Y. Ryoo, M.-H. Ryu, S.H. Yang, and B.S. Kim Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer Cancer Chemother Pharmacol 61 2007 623 629
16. N. Dong, W. Jiang, H. Li, Z. Liu, X. Xu, and M. Wang Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer Am J Clin Oncol 32 2009 559 563
17. X. Ding, X. Qu, Y. Fan, X. Che, J. Qu, and L. Xu Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells Anticancer Drugs 25 2014 315 322
18. N. Starling, S. Rao, D. Cunningham, T. Iveson, M. Nicolson, and F. Coxon Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK national cancer research institute upper gastrointestinal clinical studies group J Clin Oncol 27 2009 3786 3793